Article
HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Raises Price Target to $24
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and raises the price target from $22 to $24.
Comments
- No comments yet. Be the first to comment!